NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it
will release fourth quarter and annual 2020 financial results and
Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live
internet webcast will be held on Tuesday,
March 9, 2021, at 4:30 p.m. Eastern
Time to discuss the results.
To participate in the call, please dial 877-303-1298 (for U.S.
callers) or 253-237-1032 (for international callers). A rebroadcast
of the teleconference will be available for one week and can be
accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406
(for international callers). The Conference ID for the rebroadcast
is 7005878. The live webcast and rebroadcast can be accessed via
Cumberland's website at
http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on the delivery of high quality
prescription brands to improve patient care. The Company develops,
acquires and commercializes brands for the hospital acute care,
gastroenterology and oncology market segments. These medical
specialties are categorized by moderately concentrated prescriber
bases that the Company believes can be penetrated effectively by
targeted sales forces. The Company's portfolio of FDA-approved
brands includes:
- Acetadote® (acetylcysteine) Injection,
for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for
the treatment of pain and fever;
- Kristalose® (lactulose) for Oral
Solution, a prescription laxative, for the treatment of chronic and
acute constipation;
- Omeclamox®-Pak, (omeprazole,
clarithromycin, amoxicillin) for the treatment of Helicobacter
pylori (H. pylori) infection and related duodenal ulcer
disease;
- Vaprisol® (conivaptan) Injection, to
raise serum sodium levels in hospitalized patients with euvolemic
and hypervolemic hyponatremia;
- Vibativ® (telavancin) Injection, for
the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as
well as complicated skin and skin structure infections.
- RediTrex® (methotrexate)
Injection, for the treatment of active rheumatoid, juvenile
idiopathic and severe psoriatic arthritis, as well as disabling
psoriasis.
For more information on Cumberland's approved products, including full
prescribing information, please visit links to the individual
product websites, which can be found on the Company's website
www.cumberlandpharma.com.
The Company has Phase II clinical programs underway evaluating
its ifetroban product candidates in patients with cardiomyopathy
associated with Duchenne Muscular Dystrophy ("DMD"), Systemic
Sclerosis ("SSc") and Aspirin-Exacerbated Respiratory Disease
("AERD").
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-fourth-quarter-and-annual-2020-financial-results-301238919.html
SOURCE Cumberland Pharmaceuticals Inc.